Table 2.

Immune-related adverse events of this study population.

	n	Median duration		Grade 1, n (%)	Grade 2, n (%)	≥ Grade 3, n (%)	Corticosteroid treatment*, n (%)	Hormone replacement†, n (%)
		Day	Range
Total	166	77	3–1029	66 (39.8)	69 (41.6)	31 (18.7)	43 (25.9)	31 (18.7)
irAE subtype
Rash	44	46	4–706	28 (63.6)	12 (27.3)	4 (9.1)	11 (25.0)	0 (0.0)
Pruritus	13	87	24–771	9 (69.2)	4 (30.8)	0 (0.0)	0 (0.0)	0 (0.0)
Vitiligo	4	111	23–204	4 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Colitis/diarrhea	9	87	7–697	3 (33.3)	4 (44.4)	2 (22.2)	3 (33.3)	0 (0.0)
Thyroiditis	17	60	23–65	1 (5.9)	16 (94.1)	0 (0.0)	0 (0.0)	16 (94.1)
Hypophysitis	12	266	88–1029	0 (0.0)	10 (83.3)	2 (16.7)	0 (0.0)	12 (100.0)
Type 1 diabetes	3	192	124–407	0 (0.0)	0 (0.0)	3 (100.0)	0 (0.0)	3 (100.0)
Pneumonitis	26	70	8–361	11 (42.3)	6 (23.1)	9 (34.6)	15 (57.7)	0 (0.0)
Liver dysfunction	5	40	4–113	1 (20.0)	0 (0.0)	4 (80.0)	2 (40.0)	0 (0.0)
Renal dysfunction	3	35	17–64	1 (33.3)	1 (33.3)	1 (33.3)	1 (33.3)	0 (0.0)
Neuropathy	2	238	3–472	0 (0.0)	2 (100.0)	0 (0.0)	1 (50.0)	0 (0.0)
RA	3	259	20–331	2 (66.7)	1 (33.3)	0 (0.0)	1 (33.3)	0 (0.0)
RS3PE syndrome	2	47	8–85	0 (0.0)	2 (100.0)	0 (0.0)	2 (100.0)	0 (0.0)
Uveitis	2	62	46–78	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)
Myocarditis	2	127	127	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)
Amylase/lipase increase	2	91	60–122	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
Others	17	85	9–281	5 (29.4)	7 (41.2)	5 (29.4)	7 (41.2)	0 (0.0)

irAE immune-related adverse events, RA rheumatoid arthritis, RS3PE remitting seronegative symmetrical synovitis with pitting edema.

*Corticosteroid includes prednisolone, methylprednisolone, and dexamethasone treatment.

^†Hormone replacements includes hydrocortisone, levothyroxine, and insulin treatment.